[{"name": "Association Between the Frequent Use of Perineal Talcum Powder Products and Ovarian Cancer a Systematic Review and Meta-analysis", "features": [{"name": "Conclusion", "value": "This review suggests an increased risk of ovarian cancer associated with frequent perineal powder exposure of 31\u201365%.; Frequent perineal exposure to talc is associated with an increased risk of ovarian malignancy.; Frequent use of perineal talcum powder may be associated with an increased risk of ovarian cancer.; Frequent use of perineal talcum powder is associated with an increased risk of ovarian cancer, with a pooled adjusted odds ratio of 1.47 (95% CI 1.31, 1.65).; Perineal use of talcum powder is associated with an elevated risk of ovarian cancer, likely due to asbestiform talc fibers and asbestos fibers being the etiological agents.; the frequent use of perineal talcum powder use is associated with increased risk of ovarian cancer. These results support women avoiding the frequent use of talcum powder in the perineal area.; Examination of evidence linking powder use in genital area with ovarian cancer"}, {"name": "No. of Subjects", "value": "66,876 patients; 2527; 6542 ovarian cancer cases and 66,876 women; 52191; 10 case-control studies and a single cohort study"}, {"name": "Relative Risk", "value": "1.47 (95% CI 1.31, 1.65, P<0.0001); Adjusted hazard ratio and odds ratio with 95% CI were reported.; Adjusted odds ratios and the adjusted hazard ratio were combined given the infrequency of ovarian cancer.; 1.47; 1.47; Increased risk of ovarian cancer"}, {"name": "Length of Follow", "value": "Not mentioned explicitly; Not specified"}, {"name": "Meta-analysis Guidelines", "value": "Meta-analysis of Observational Studies in Epidemiology guidelines"}, {"name": "Quality Assessment Tool", "value": "Newcastle-Ottawa Scale (NOS)"}, {"name": "Type of Studies Included", "value": "Case-control and cohort studies"}, {"name": "Length of Follow-up", "value": "Not specified"}, {"name": "Search Strategy", "value": "Comprehensive searches were performed in PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials."}, {"name": "Eligibility Criteria and Study Selection", "value": "Observational cohort and case-control study designs were included if they reported primary data on frequent perineal exposure to talc."}, {"name": "Assessment of Risk of Bias and Study Quality", "value": "The studies were independently reviewed for quality using the Newcastle Ottawa Scale."}, {"name": "Heterogeneity", "value": "24.4% (P=0.22) of the variation across studies were due to heterogeneity."}, {"name": "Publication Bias", "value": "Publication bias was evaluated by visual inspection of the funnel plot and statistically with Egger\u2019s test.; None"}, {"name": "Study Design", "value": "10 retrospective case-control studies and a single cohort study"}, {"name": "Type of Study", "value": "Meta-analysis; Systematic Review"}, {"name": "Frequency and Duration of Talcum Powder Use", "value": "Multiple times per week"}, {"name": "Type of Talcum Powder Exposure", "value": "Perineal"}, {"name": "Supplementary Information", "value": "supplementary material available at https://doi.org/10.1007/s11606-022-07414-7."}, {"name": "Acknowledgements", "value": "Evans Whitaker, MD MLIS, Katie O\u2019Brien, PhD"}, {"name": "Conflict of Interest", "value": "Sean Woolen: No relevant disclosures. Ann A Lazar: No relevant disclosures. Rebecca Smith-Bindman: Served as a paid expert witness for the plaintiffs in the talcum powder litigation."}, {"name": "Carcinogenic hazards", "value": "International Agency for Research on Cancer Monographs"}, {"name": "Use of Powder in the Genital Area", "value": "Examining the evidence"}, {"name": "Genital Powder Use", "value": "Link with Ovarian Cancer"}]}]